Session Information

Session Moderator

21:00 - 21:00  |  Presenter: Yi-Long Wu

Session Moderator

21:00 - 21:00  |  Presenter: Chunxue Bai

Session Moderator

21:00 - 21:00  |  Presenter: Caicun Zhou

Session Moderator

21:00 - 21:00  |  Presenter: Karen Kelly

WS08.01 - Session Introduction

21:00 - 21:02  |  Presenter: Yi-Long Wu

WS08.02 - Session Introduction

21:02 - 21:04  |  Presenter: Chunxue Bai

WS08.03 - Session Introduction

21:04 - 21:07  |  Presenter: Caicun Zhou

WS08.04 - Session Introduction

21:07 - 21:10  |  Presenter: Karen Kelly

WS08.05 - Minimal Residual Disease (MRD) Negative: Potential for Cure in Resected Oncogene Driven NSCLC? Chinese Perspective

21:10 - 21:30  |  Presenter: Jia-Tao Zhang

WS08.06 - Could MRD Change Our Clinical Practice? North American Perspective

21:30 - 21:50  |  Presenter: Aadel Chaudhuri

WS08.07 - How to Use Liquid Biopsy to Monitor Treatment Efficacy for Advanced Driven NSCLC

21:50 - 22:10  |  Presenter: Jie Hu

WS08.08 - Liquid Biopsy for Advanced Oncogene Driven NSCLC. European Perspective

22:10 - 22:30  |  Presenter: Martin Filipits

WS08.09 - Sintilimab versus Pembrolizumab as Monotherapy or in Combination with Chemotherapy for Treatment Naïve Metastatic Non-small Cell Lung Cancer

22:30 - 22:40  |  Presenter: Si-Yang Maggie Liu

WS08.10 - Toripalimab in Combination with CIK Cells in Patients with Advanced NSCLC: An Exploratory Study

22:40 - 22:50  |  Presenter: Xuxinyi Ling

WS08.11 - Entrectinib in Patients with ROS1 Fusion-Positive (ROS1-fp) NSCLC: Updated Efficacy and Safety Analysis

22:50 - 23:00  |  Presenter: Yun Fan

WS08.12 - Discussant for Oral Abstracts

23:00 - 23:20  |  Presenter: Sai-Hong Ignatius Ou

WS08.13 - Activity of aPD1-MSLN-CART Cells Against Metastatic Lung Cancer in a Phase 1 Trial

23:20 - 23:21  |  Presenter: Xiaorong Dong

WS08.14 - Final Analyses of ALTER-L018: A Randomized Phase II Trial of Anlotinib Plus Docetaxel vs Docetaxel as 2nd-line Therapy for EGFR-Negative NSCLC

23:21 - 23:22  |  Presenter: Lin Wu

WS08.15 - Safety and Efficacy of Sitravatinib + Tislelizumab in Patients with PD-L1+, Locally Advanced/Metastatic, Squamous NSCLC

23:22 - 23:23  |  Presenter: Jun Zhao

WS08.16 - The Increase of Blood Intratumor Heterogeneity is Associated with Unfavorable Outcomes of ICIs Plus Chemotherapy in NSCLC

23:23 - 23:24  |  Presenter: Juan Zhou

WS08.17 - Utilization of Tumor Mutational Profiling to Identify the Immunotherapy Response in Non-small Cell Lung Cancer

23:24 - 23:25  |  Presenter: Wenbin Li

WS08.18 - Discussant for Poster 1 - 5

23:25 - 23:40  |  Presenter: Xiaorong Dong

WS08.19 - Phase Il Trial of Neoadjuvant Tislelizumab with Chemotherapy for Resectable Stage IIB-III Non-small Cell Lung Cancer

23:40 - 23:41  |  Presenter: Yao-Bin Lin

WS08.20 - Comprehensive Analysis of a Dendritic Cell Marker Genes Signature to Predict Prognosis and Immunotherapy Response in Lung Adenocarcinoma

23:41 - 23:42  |  Presenter: Yuan Li

WS08.21 - Immune Evolution of Metastases & Underlying Molecular Mechanisms in Non-small Cell Lung Cancer

23:42 - 23:43  |  Presenter: Wen-Fang Tang

WS08.22 - Neoadjuvant Toripalimab Combination in Patients with Stage IIB-IIIB NSCLC: A Single-arm, Phase 2 Trial (Renaissance Study)

23:43 - 23:44  |  Presenter: Shi Yan

WS08.23 - Transcriptomic Heterogeneity in Non-Small Cell Lung Cancer with Four Structure-Based EGFR-Mutation Subgroups

23:44 - 23:45  |  Presenter: Shun Lu

WS08.24 - Discussant for Poster 6 - 10

23:35 - 23:50  |  Presenter: Ming Fang Zhao

MA02.05 - Dynamic Mutation Profiles of SCLC Transformation in NSCLC Patients Harboring Concurrent EGFR/TP53/RB1 Mutations

10:57 - 11:02  |  Presenter: Jie Huang

OA02.05 - Sugemalimab vs Placebo after cCRT or sCRT in pts with Unresectable Stage III NSCLC: Final PFS Analysis of a Phase 3 Study

12:22 - 12:32  |  Presenter: Yi-Long Wu

OA03.05 - Tepotinib in Patients with MET Exon 14 (METex14) Skipping NSCLC: Primary Analysis of the Confirmatory VISION Cohort C

14:52 - 15:02  |  Presenter: Michael Thomas

EP08.01-070 - Safety and Efficacy of Sitravatinib + Tislelizumab in Patients with PD-L1+, Locally Advanced/Metastatic, Squamous NSCLC

EP08.01-071 - Safety and Efficacy of Sitravatinib + Tislelizumab in Patients with PD-L1+, Locally Advanced/Metastatic, Non-Squamous NSCLC

EP08.01-085 - Sintilimab versus Pembrolizumab as Monotherapy or in Combination with Chemotherapy for Treatment Naïve Metastatic Non-small Cell Lung Cancer

EP08.02-049 - A Phase I Trial of the HER2 Exon 20 Inhibitor, BI 1810631, In Patients With Advanced Solid Tumors With HER2 Aberrations

EP08.02-063 - SANOVO: A Phase 3 Study of Savolitinib or Placebo in Combination with Osimertinib in Patients with EGFR-mutant and MET Overexpressed NSCLC

EP08.02-064 - ASTRIS China: A Real-world Study of Osimertinib in Patients with EGFR T790M Positive Non-small-cell Lung Cancer (NSCLC)

EP08.02-108 - Osimertinib Long-Term Tolerability in Patients with EGFRm NSCLC Enrolled in the AURA Program or FLAURA Study

EP10.01-010 - Real-world Study of the Incidence and Risk Factors of Venous Thromboembolism in Chinese Lung Cancer (RIVAL)

EP16.01-025 - Immune Evolution of Metastases & Underlying Molecular Mechanisms in Non-small Cell Lung Cancer

EP16.02-024 - Plasma ctDNA Organ-Specific Genomic Patterns and Origination Analysis in Advanced Non-Small Cell Lung Cancer

OA15.06 - Pooled Analysis of Outcomes With Second-Course Pembrolizumab Across 5 Phase 3 Studies of Non-Small-Cell Lung Cancer

15:02 - 15:12  |  Presenter: Delvys Rodriguez-Abreu